P0995Impact of ileocaecal resection on quality of life in patients with Crohn’s Disease: a cross-sectional survey

Abstract Background Ileocaecal resection (ICR) is an effective and frequently required surgical treatment for Crohn’s disease (CD). Quality of life (QoL), commonly measured by the Inflammatory Bowel Disease Questionnaire (IBDQ), strongly influences treatment decisions, yet studies integrating patient-reported QoL with objective clinical parameters remain limited. This study aimed to evaluate postoperative QoL and identify clinical factors associated with IBDQ-defined remission following ICR in Crohn’s disease. Methods This cross-sectional study included CD patients who underwent ICR at a tertiary centre between 1989 and 2024 with ≥ 3 months of postoperative follow-up. QoL was assessed using the IBDQ and supplementary items. Clinical and laboratory data, including the Crohn’s Disease Activity Index (CDAI), inflammatory markers, and nutritional/biochemical indices (body mass index (BMI), albumin), were retrieved from medical records. Clinical remission was defined as IBDQ ≥ 170 (IBDQ-defined remission). Correlations between clinical variables and IBDQ scores were analysed, and independent factors of IBDQ remission were assessed using multivariable logistic regression. Results A total of 189 patients were analysed (65.6% male; median age 37.1 years). The median CD duration was 13.1 years and postoperative duration 112 months. The mean IBDQ total score was 183.7 ± 25.4, with 71.4% of patients achieving remission (≥ 170). Patients also reported marked postoperative improvement in abdominal pain, stool frequency, and social functioning. Pain intensity measured by the Visual Analogue Scale (VAS) correlated negatively with all IBDQ domains (r ≈ –0.3, p 0.01). Patients with ≤ 3 bowel movements per day had significantly higher QoL (187.1 vs 171.8, p 0.001), and earlier return to daily life (≤ 3 months) was associated with higher social and emotional scores (p 0.05). In multivariable analysis, lower current CDAI (OR 0.988, 95% CI 0.980–0.995, p = 0.001) and lower bowel frequency (OR 0.766, 95% CI 0.602–0.976, p = 0.031) at the time of survey were independent factors of IBDQ-defined remission. IBDQ scores did not differ according to postoperative duration, suggesting comparable QoL across different follow-up periods. In addition, patient-reported overall satisfaction was high (91.5%), and 89.4% indicated they would undergo surgery again. Conclusion ICR was associated with favourable QoL and high patient satisfaction. From the clinical perspective, maintaining QoL among patients in remission requires continuous control of disease activity and stable bowel habits. These findings emphasise both patient-centred benefits and the need for meticulous postoperative management to optimise long-term patient-reported outcomes. References: 1. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96(3):804-810. 2. Kim WJ, Iskandarani M, Manzo CA, Pellino G, Gallostra MM, Tekkis PP, et al. Patient-reported outcome measures and surgery for Crohn’s disease: systematic review. BJS Open. 2023;7(5):zrad098. 3. D’Ugo S, Romano F, Sibio S, Bagaglini G, Sensi B, Biancone L, et al. Impact of surgery on quality of life in Crohn’s disease: short- and mid-term follow-up. Updates Surg. 2020;72(3):773-780. 4. Bemelman WA, Warusavitarne J, Sampietro GM, Serclova Z, Zmora O, Luglio G, et al. ECCO-ESCP consensus on surgery for Crohn’s disease. J Crohns Colitis. 2018;12(1):1-16. Conflict of interest: Mr. Hong, Jueon: No conflict of interest Park, Suhyun: No conflict of interest Kwon, Eunja: No conflict of interest Kim, Sewoong: No conflict of interest Lee, Junghwa: No conflict of interest Kim, Min Kyu: No conflicts Hong, Seung Wook: No conflict of interest Hwang, Sung Wook: no conflicts Yang, Dong-Hoon: Nothing to declare Ye, Byong Duk: Byong Duk Ye reports consulting fees from AbbVie Korea, BMS Pharmaceutical Korea Ltd., Celltrion, Chong Kun Dang Pharm, CJ Red BIO, Curacle, Daewoong Pharm, Dong-A ST, Ferring Korea, Hanmi Pharmaceutical, Imscout, IQVIA, Johnson & Johnson, Johnson & Johnson Korea, Jeil Pharmaceutical Co., Kangstem Biotech, Korea Otsuka Pharm, Korea United Pharm, Lilly Korea, Medtronic Korea, NanoEntek, ORGANOIDSCIENCES Ltd., Pfizer Korea, Samsung Bioepis, Takeda, Takeda Korea and Yuhan speaker fees from AbbVie Korea, BMS Pharmaceutical Korea Ltd., Celltrion, Cornerstones Health, Curacle, Daewoong Pharm, Eisai Korea, Ferring Korea, IQVIA, Johnson & Johnson Korea, Pfizer Korea, Samsung Bioepis, and Takeda Korea and research support from Celltrion and Pfizer Korea. Byeon, Jeong-Sik: - Clinical study grants from Olympus Co, GC genome, Pharmbio Korea Inc, and Taejoon Pharm. Clinical studies related to the grants include artificial intelligence endoscopy for colon polyp detection/diagnosis, cfDNA for colorectal cancer screening, and colonoscopy bowel preparation. - I am a medical advisor of AINEX corporation, Korea, which is an AI endoscopy company. Myung, Seung-Jae: No conflict of interest Yang, Suk-Kyun: No conflict of interest Lee, Jong Lyul: No conflict of interest Yoon, Yong Sik: No conflict of interest Yu, Chang Sik: No conflict of interest Park, Sang Hyoung: No conflict of interest